



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	133.95
Trade Time:	10:42 AM ET Jul 28, 2017
Change:	-0.20 (0.149%)
Day Range	133.19 - 135.13
52-Week Range	96.93 - 139.00
Volume	967,155

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 28, 2017

[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

Jul 27, 2017

[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)

Jul 25, 2017

[Celgene Corporation Announces Settlement of Civil Litigation](#)

Jul 5, 2017

[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

Jul 5, 2017

[Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017](#)

Upcoming Events [\[View all \]](#)

Aug 9, 2017 3:00 PM ET

[Canaccord Genuity 37th Annual Growth Conference](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)

Oct 27, 2016

[Quarterly Report \(10-Q\)](#)